Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | DRD3 | P35462 | 4/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10849611 | 0.84 | DRD2 (0.62) | DRD2DRD3HSP90AB1 | |
| SCHEMBL11105049 | 0.81 | DRD2 (0.59) | DRD2DRD3ADRA2CMEN1KMT2A | |
| SCHEMBL30547268 | 0.80 | RECQL (0.68) | DRD2DRD3ADRA2CMEN1USP2 | |
| SCHEMBL11626341 | 0.80 | RECQL (0.68) | DRD2DRD3ADRA2CMEN1USP2 | |
| SCHEMBL17764863 | 0.80 | ADRA2C (0.65) | DRD2DRD3ADRA2CKEAP1MEN1 | |
| SCHEMBL23152040 | 0.78 | ADRA2C (0.79) | DRD2DRD3ADRA2CHSP90AB1KEAP1 | |
| SCHEMBL11775877 | 0.78 | ADRA2C (0.79) | DRD2DRD3ADRA2CHSP90AB1KEAP1 | |
| SCHEMBL11622263 | 0.78 | ALDH1A1 (0.68) | DRD2DRD3ADRA2CMEN1GAA | |
| SCHEMBL15540352 | 0.77 | DRD2 (0.48) | DRD2DRD3HSP90AB1MEN1GAA | |
| Hydrochloric Acid SCHEMBL11754729 | 0.77 | ALDH1A1 (0.66) | DRD2DRD3ADRA2CMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | DRD2 2358/4885DRD3 3026/4885ADRA2C 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.